Decreased Expression of CD247 and CD4 Immune Marker Predicts Poor Prognosis in Triple Negative Breast Cancer

Pateriya, Ankit; Nema, Rajeev; Mishra, Anand Kumar; Kumar, Ashok; Shrivastava, Ashutosh

doi:10.31557/APJCP.2024.25.9.3187

Decreased Expression of CD247 and CD4 Immune Marker Predicts Poor Prognosis in Triple Negative Breast Cancer

Document Type : Research Articles

Authors

¹ Centre for Advance Research, Faculty of Medicine, King George’s Medical University, Lucknow, India.

² Department of Biosciences Manipal University Jaipur, Dehmi Kalan, Jaipur-Ajmer Expressway, Jaipur, Rajasthan, India.

³ Department of Endocrine Surgery, Faculty of Medicine, King George’s Medical University, Lucknow, Uttar Pradesh, India.

⁴ Department of Biochemistry, All India Institute of Medical Sciences (AIIMS) Bhopal, Saket Nagar, Bhopal, India.

10.31557/APJCP.2024.25.9.3187

Abstract

Objective: Triple negative breast cancer (TNBC) is an aggressive from of breast cancer and is associated with poor prognosis. Tumor microenvironment of breast cancer consists of a wide range of cell types, including tumor-infiltrating lymphocytes (TILs). Accumulating evidence indicate that TILs play a crucial role in cancer progression and resistance to standard chemotherapy. Method: We used online computational tools to evaluate the prognostic significance of CD247 and CD4 in TNBC. Results: TNBC patients with lower expression of CD247 and CD4 have much shorter relapse- free survival and overall survival than the patients with higher expression of these genes. CD247 and CD4 expression show a strong positive correlation with tumor-infiltrating dendritic cells, B-cells, CD4+, CD8+, and neutrophils. Conclusion: We’ve concluded that low levels of CD247 and CD4 may stop immune cells from entering the area around the tumor, which stops cancer cells from being killed and gives the patient a bad outlook. These findings suggest that CD247 and CD4 may be useful biomarkers or as a target to understand the progression of TNBC. Our findings also suggest that CD247 and CD4 targeted therapeutics should be explored in detail, and could be a potentially used as atreatment strategy for TNBC.

Keywords